Eterus Capital has acquired an additional stake in GroupSolver
Eterus Capital, a.s. has acquired an additional stake in GroupSolver Inc.
Founded in 2008, Eterus Capital is an investor targeting small and medium-sized companies with growth potential, which have successfully proved their business concept. The fund only invests in minority positions while management control always remains in the hands of the original shareholders
GroupSolver is a market research technology company based in San Diego, California, with operations in Utah in the US, and Slovakia. It has built an intelligent market research platform “online survey with a brain” that helps businesses answer their burning why, how and what questions faster and with more confidence. By combining machine learning and crowd intelligence, the GroupSolver® technology helps decision-makers and researchers find insights that traditionally remain hidden from online surveys or focus groups.
Oaklins’ team in Slovakia acted as the exclusive sell-side advisor in this transaction, which was a follow-up from a previous investment in June 2020.
Talk to the deal team
Related deals
Den Berk Délice accelerates growth through strategic partnership
Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.
Learn moreMicrofinanciera Fundeser has been sold to Grupo Financiero Atlántida
Incofin has successfully exited its investment in Microfinanciera Fundeser in Nicaragua through two of its funds: Rural Impulse Fund II (RIF II) and agRIF. It has sold 100% of its stake in Microfinanciera Fundeser to Grupo Financiero Atlántida through its subsidiary, Inversiones Tres Lagos.
Learn moreBayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn more